The latest update is out from OpGen Inc (OPGN).
OpGen, Inc. has appointed David Lazar as its new CEO, effective April 1, 2024, with an annual salary of $406,000, to be deferred until the company’s liquidity allows for payment. Lazar, who has extensive leadership experience including a role as CEO of Titan Pharmaceuticals and board positions at several companies, will also be eligible for various bonuses. His term is set for three years, and he currently serves as OpGen’s Chairman of the Board, bringing a wealth of experience as a custodian and advisor in diverse industries.
Learn more about OPGN stock on TipRanks’ Stock Analysis page.
